News
A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding. A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding.
Read more
New data from Axcella, PepGen, Dystrogen and Galecto are showing promise in challenging diseases, including NASH, Duchenne muscular dystrophy and myelofibrosis.
Read more
Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive 6-month results from an ongoing clinical study conducted in Poland under a hospital exemption protocol of DT-DEC01, the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).
Read more
Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).
Read more
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that it has received U.S. Food & Drug Administration (FDA) 510(k) clearance for its HOLO Portal surgical guidance system for use within lumbar spine procedures.
Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).
Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announces the completion of the acquisition of Holo Surgical Inc., (‘Holosurgical’), a Chicago-based private technology company developing the revolutionary Augmented Reality and Artificial Intelligence platform (‘ARAI™’).
Artificial Intelligence Technology Will Enable Computers to Autonomously Identify and Segment Neural Structures in Medical Images and Provide Reference Information Regarding Pathological States.
DYST 201, a gene therapy targeting the mutated forms of the gene responsible for Huntington’s disease, has shown promising results, Dystrogen Therapeutics announced.
The ARAI™ is an advanced digital surgery platform that combines 3D visualization, data analytics, and machine learning to improve outcomes, reduce surgical time, and decrease surgical complications. The clinically-tested ARAI™ surgical guidance system provides real-time, patient-specific, 3D anatomical visualization for pre-surgical planning, real-time intraoperative guidance, and postsurgical data analytics.
